{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T03:07:48Z","timestamp":1775012868055,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,12,22]],"date-time":"2009-12-22T00:00:00Z","timestamp":1261440000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s10096-009-0848-8","type":"journal-article","created":{"date-parts":[[2009,12,21]],"date-time":"2009-12-21T09:50:55Z","timestamp":1261389055000},"page":"259-267","source":"Crossref","is-referenced-by-count":34,"title":["Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers"],"prefix":"10.1007","volume":"29","author":[{"given":"S. A.","family":"Halperin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Diaz-Mitoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Dull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Anemona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ceddia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,12,22]]},"reference":[{"key":"848_CR1","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/520303","volume":"26","author":"L Erickson","year":"1998","unstructured":"Erickson L, De Wals P (1998) Complications and sequelae of meningococcal disease in Quebec, Canada, 1990\u20131994. Clin Infect Dis 26:1159\u20131164","journal-title":"Clin Infect Dis"},{"issue":"5","key":"848_CR2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/01.inf.0000259996.95965.ef","volume":"26","author":"O Bilukha","year":"2007","unstructured":"Bilukha O, Messonnier N, Fischer M (2007) Use of meningococcal vaccines in the United States. Pediatr Infect Dis J 26(5):371\u2013376","journal-title":"Pediatr Infect Dis J"},{"issue":"12 Suppl","key":"848_CR3","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1097\/01.inf.0000147642.85129.05","volume":"23","author":"AJ Pollard","year":"2004","unstructured":"Pollard AJ (2004) Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 23(12 Suppl):S274\u2013S279","journal-title":"Pediatr Infect Dis J"},{"key":"848_CR4","unstructured":"Centers for Disease Control and Prevention (CDC), Active Bacterial Core Surveillence Reports, Emerging Infectious Program Network, Neisseria Meningitidis. 2005"},{"key":"848_CR5","volume-title":"Control of epidemic meningococcal disease: WHO practical guidelines","author":"World Health Organization (WHO)","year":"1998","unstructured":"World Health Organization (WHO) (1998) Control of epidemic meningococcal disease: WHO practical guidelines, 2nd edn. WHO, Geneva","edition":"2"},{"key":"848_CR6","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/jama.280.19.1685","volume":"280","author":"NE MacDonald","year":"1998","unstructured":"MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM (1998) Induction of immunologic memory by conjugated vs. plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 280:1685\u20131689","journal-title":"JAMA"},{"key":"848_CR7","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1172\/JCI108235","volume":"56","author":"R Gold","year":"1975","unstructured":"Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC (1975) Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 56:1536\u20131547","journal-title":"J Clin Invest"},{"key":"848_CR8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/INF.0b013e3181861dba","volume":"28","author":"MD Snape","year":"2009","unstructured":"Snape MD, MacLennan JM, Lockhart S, English M, Yu L-M, Moxon RE, Pollard AJ (2009) Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine. Pediatr Infect Dis J 28:92\u201397","journal-title":"Pediatr Infect Dis J"},{"key":"848_CR9","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/00006454-199809001-00005","volume":"17","author":"PT Heath","year":"1998","unstructured":"Heath PT (1998) Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 17:S117\u2013S122","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"848_CR10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1473-3099(04)01251-4","volume":"5","author":"MD Snape","year":"2005","unstructured":"Snape MD, Pollard AJ (2005) Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 5(1):21\u201330","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"848_CR11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5694\/j.1326-5377.2007.tb00828.x","volume":"186","author":"R Booy","year":"2007","unstructured":"Booy R, Jelfs J, El Bashir H, Nissen MD (2007) Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust 186(3):108\u2013109","journal-title":"Med J Aust"},{"key":"848_CR12","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","volume":"23","author":"A Larrauri","year":"2005","unstructured":"Larrauri A, Cano R, Garc\u00eda M, de Mateo S (2005) Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23:4097\u20134100","journal-title":"Vaccine"},{"key":"848_CR13","first-page":"794","volume":"56","author":"Centers for Disease Control and Prevention (CDC)","year":"2007","unstructured":"Centers for Disease Control and Prevention (CDC) (2007) Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11\u201318\u00a0years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep 56:794\u2013795","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"848_CR14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.inf.0000126297.28952.f8","volume":"23","author":"M Rennels","year":"2004","unstructured":"Rennels M, King J Jr, Ryall R, Papa T, Froeschle J (2004) Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 23:429\u2013435","journal-title":"Pediatr Infect Dis J"},{"key":"848_CR15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1086\/500512","volume":"193","author":"DM Vu","year":"2006","unstructured":"Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM (2006) Antibody persistence 3\u00a0years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 193:821\u2013828","journal-title":"J Infect Dis"},{"key":"848_CR16","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129:1307\u20131326","journal-title":"J Exp Med"},{"key":"848_CR17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","volume":"299","author":"M Snape","year":"2008","unstructured":"Snape M, Perrett K, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ (2008) Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299:173\u2013184","journal-title":"JAMA"},{"key":"848_CR18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/INF.0b013e31818e037d","volume":"28","author":"KP Perrett","year":"2009","unstructured":"Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ (2009) Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 28:186\u2013193","journal-title":"Pediatr Infect Dis J"},{"key":"848_CR19","first-page":"1265","volume":"56","author":"Centers for Disease Control and Prevention (CDC)","year":"2007","unstructured":"Centers for Disease Control and Prevention (CDC) (2007) Notice to Readers: Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2\u201310\u00a0years at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 56:1265\u20131266","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"848_CR20","unstructured":"Public Health Agency of Canada. Publicly funded immunization programs in Canada\u2014routine schedule for infants and children (including special programs and catch-up programs). Available online at: http:\/\/www.phac-aspc.gc.ca\/im\/ptimprog-progimpt\/table-1-eng.php . Accessed 17 February 2009"},{"key":"848_CR21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4161\/hv.2.2.2611","volume":"2","author":"CL Trotter","year":"2006","unstructured":"Trotter CL, Edmunds WJ, Ramsay ME, Miller E (2006) Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales. Hum Vaccin 2:68\u201373","journal-title":"Hum Vaccin"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-009-0848-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-009-0848-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-009-0848-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T09:19:05Z","timestamp":1634375945000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-009-0848-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,22]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1007\/s10096-009-0848-8","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,22]]}}}